Erratum to Parameningeal rhabdomyosarcoma in pediatric age: Results of a pooled analysis from North American and European Cooperative Groups [Ann Oncol, 5, (2014) 231-236] DOI: 10.1093/annonc/mdt426;Parameningeal rhabdomyosarcoma in pediatric age: Results of a pooled analysis from North American and European cooperative groups

Annals of Oncology

Volumn 25, Issue 1, 2014, Pages 231-236

  Merks, J H M ^a   de Salvo, G L ^b   Bergeron, C ^c   Bisogno, G ^d   de Paoli, A ^b   Ferrari, A ^e   Rey, A ^f   Oberlin, O ^f   Stevens, M C G ^g   Kelsey, A ^h   Michalski, J ⁱ   Hawkins, D S ^j   Anderson, J R ^k  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^c CENTRE LÉON BÉRARD   (France)

^d Clinic of Pediatric Oncology Hematology   (Italy)

^e NATIONAL CANCER INSTITUTE   (Italy)

^f INSTITUT GUSTAVE ROUSSY   (France)

^g Royal Hospital for Children   (United Kingdom)

^h ROYAL MANCHESTER CHILDREN S HOSPITAL   (United Kingdom)

ⁱ Washington University School of Medicine   (United States)

^j UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^k UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

more..

Author keywords

Meningeal involvement; Parameningeal; Radiotherapy; Rhabdomyosarcoma

Indexed keywords

AGE DISTRIBUTION; ARTICLE; BRAIN HISTOLOGY; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHILD; CONTROLLED STUDY; EUROPE; EVENT FREE SURVIVAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NORTH AMERICA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PARAMENINGEAL DISORDER; PARAMENINGEAL RHABDOMYOSARCOMA; PREDICTIVE VALUE; PRIORITY JOURNAL; RHABDOMYOSARCOMA; SURVIVAL PREDICTION; SURVIVAL TIME; TUMOR INVASION; TUMOR VOLUME;

MENINGEAL INVOLVEMENT; PARAMENINGEAL; RADIOTHERAPY; RHABDOMYOSARCOMA;

CENTRAL NERVOUS SYSTEM NEOPLASMS; COMBINED MODALITY THERAPY; HUMANS; KAPLAN-MEIER ESTIMATE; MULTIVARIATE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RHABDOMYOSARCOMA;

EID: 84905391526     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu001     Document Type: Erratum

References (22)

1. Miller RW, Young JL, Jr, Novakovic B. Childhood cancer. Cancer 1995; 75: 395-405.
2. Arndt CA, Stoner JA, Hawkins DS et al. Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: Children's Oncology Group study D9803. J Clin Oncol 2009; 27: 5182-5188.
3. Dantonello TM, Int-Veen C, Harms D et al. Cooperative trial CWS-91 for localized soft tissue sarcoma in children, adolescents, and young adults. J Clin Oncol 2009; 27: 1446-1455.
4. Oberlin O, Rey A, Sanchez de Toledo J et al. Randomized comparison of intensified six-drug versus standard three-drug chemotherapy for high-risk nonmetastatic rhabdomyosarcoma and other chemotherapy-sensitive childhood soft tissue sarcomas: long-term results from the International Society of Pediatric Oncology MMT95 study. J Clin Oncol 2012; 30: 2457-2465.
5. Raney RB, Meza J, Anderson JR et al. Treatment of children and adolescents with localized parameningeal sarcoma: experience of the Intergroup Rhabdomyosarcoma Study Group protocols IRS-II through -IV, 1978-1997. Med Pediatr Oncol 2002; 38: 22-32.
6. Hawkins DS, Anderson JR, Paidas CN et al. Improved outcome for patients with middle ear rhabdomyosarcoma: a Children's Oncology Group study. J Clin Oncol 2001; 19: 3073-3079.
7. Benk V, Rodary C, Donaldson SS et al. Parameningeal rhabdomyosarcoma: results of an international workshop. Int J Radiat Oncol Biol Phys 1996; 36: 533-540.
8. Raney B, Anderson J, Jenney M et al. Late effects in 164 patients with rhabdomyosarcoma of the bladder/prostate region: a report from the international workshop. J Urol 2006; 176: 2190-2194.
9. Oberlin O, Rey A, Anderson J et al. Treatment of orbital rhabdomyosarcoma: survival and late effects of treatment-results of an international workshop. J Clin Oncol 2001; 19: 197-204.
10. Oberlin O, Rey A, Lyden E et al. Prognostic factors in metastatic rhabdomyosarcomas: results of a pooled analysis from United States and European cooperative groups. J Clin Oncol 2008; 26: 2384-2389.
11. Arndt C, Tefft M, Gehan E et al. A feasibility, toxicity, and early response study of etoposide, ifosfamide, and vincristine for the treatment of children with rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study (IRS) IV pilot study. J Pediatr Hematol Oncol 1997; 19: 124-129.
12. Crist W, Gehan EA, Ragab AH et al. The third Intergroup Rhabdomyosarcoma Study. J Clin Oncol 1995; 13: 610-630.
13. Crist WM, Anderson JR, Meza JL et al. Intergroup Rhabdomyosarcoma Study-IV: results for patients with nonmetastatic disease. J Clin Oncol 2001; 19: 3091-3102.
14. Bisogno G, De RC, Gamboa Y et al. Improved survival for children with parameningeal rhabdomyosarcoma: results from the AIEOP soft tissue sarcoma committee. Pediatr Blood Cancer 2008; 50: 1154-1158.
15. Flamant F, Rodary C, Rey A et al. Treatment of non-metastatic rhabdomyosarcomas in childhood and adolescence. Results of the second study of the International Society of Paediatric Oncology: MMT84. Eur J Cancer 1998; 34: 1050-1062.
16. Stevens MC, Rey A, Bouvet N et al. Treatment of nonmetastatic rhabdomyosarcoma in childhood and adolescence: third study of the International Society of Paediatric Oncology-SIOP Malignant Mesenchymal Tumor 89. J Clin Oncol 2005; 23: 2618-2628.
17. Raney RB, Asmar L, Vassilopoulou-Sellin R et al. Late complications of therapy in 213 children with localized, nonorbital soft-tissue sarcoma of the head and neck: a descriptive report from the Intergroup Rhabdomyosarcoma Studies (IRS)-II and -III. IRS Group of the Children's Cancer Group and the Pediatric Oncology Group. Med Pediatr Oncol 1999; 33: 362-371.
18. Defachelles AS, Rey A, Oberlin O et al. Treatment of nonmetastatic cranial parameningeal rhabdomyosarcoma in children younger than 3 years old: results from International Society of Pediatric Oncology studies MMT 89 and 95. J Clin Oncol 2009; 27: 1310-1315.
19. Michalski JM, Meza J, Breneman JC et al. Influence of radiation therapy parameters on outcome in children treated with radiation therapy for localized parameningeal rhabdomyosarcoma in Intergroup Rhabdomyosarcoma Study Group trials II through IV. Int J Radiat Oncol Biol Phys 2004; 59: 1027-1038.
20. Donaldson SS, Meza J, Breneman JC et al. Results from the IRS-IV randomized trial of hyperfractionated radiotherapy in children with rhabdomyosarcoma-a report from the IRSG. Int J Radiat Oncol Biol Phys 2001; 51: 718-728.
21. Lin C, Donaldson SS, Meza JL et al. Effect of radiotherapy techniques (IMRT vs. 3D-CRT) on outcome in patients with intermediate-risk rhabdomyosarcoma enrolled in COG D9803-a report from the Children's Oncology Group. Int J Radiat Oncol Biol Phys 2012; 82: 1764-1770.
22. Buwalda J, Schouwenburg PF, Blank LE et al. A novel local treatment strategy for advanced stage head and neck rhabdomyosarcomas in children: results of the AMORE protocol. Eur J Cancer 2003; 39: 1594-1602.